Navigation Links
Fertility Drugs Contribute Heavily to Multiple Births
Date:6/16/2010

March of Dimes Concerned About Drugs' Role in Crisis of Prematurity

WHITE PLAINS, N.Y., June 16 /PRNewswire-USNewswire/ -- The widespread use of fertility drugs, not just high-tech laboratory procedures, plays a major role in causing multiple births and  contributes to the problem of premature birth in the United States, experts said today at the March of Dimes National Communications Advisory Council luncheon.

Working with experts from the U.S. Centers for Disease Control and Prevention (CDC), Joann Petrini, PhD, assistant director of research at Danbury Hospital in Connecticut and an advisor to the March of Dimes, found that controlled ovarian hyperstimulation (COH) drugs — which are used to stimulate a woman's ovaries to speed the maturity and multiply the production of eggs — account for four times more live births than assisted reproductive technologies (ARTs) such as in vitro fertilization. 

"Many people have focused on the role of ARTs in multiples and have not fully appreciated that fertility drugs alone are responsible for one out of every five multiple births," said Dr. Petrini. "There is a very high possibility of multi-fetal pregnancy resulting from these drugs, and that brings a high risk of prematurity and lifelong health problems for the babies as a consequence."

Patients should inform their doctors that their goal is a single baby and that they wish them to use treatments that minimize the risk of multiple pregnancy, said Richard Dickey, MD, PhD, medical director of The Fertility Institute of New Orleans and Clinical Professor of Obstetrics and Gynecology at the Louisiana State University Health Sciences School of Medicine at New Orleans.

"A doctor's goal when prescribing fertility drugs is one healthy baby," said Dr. Dickey. "Doctors should not hesitate to cancel ovulation stimulation cycles and to tell their patients to avoid trying to get pregnant if an ultrasound shows there are too many eggs present in a cycle and the risk of multiples is high. "The March of Dimes urges more research and leadership from professional societies to develop specific guidelines and encourage acceptance of best practices for the proper use and dosage of fertility drugs, as well as the careful counseling and monitoring of women treated with these drugs.  Also, the March of Dimes said a system is needed to monitor how many multiples births are caused by fertility drugs and to hold professionals accountable to industry guidelines. Women who are taking fertility drugs should always ask their doctor what they can do to prevent having a multi-fetal pregnancy.

About 88,000 babies are born preterm annually as a result of the recent increase of twins, triplets, and other multiple births.  About 60 percent of twins, more than 90 percent of triplets and virtually all quadruplets and higher-order multiples are born prematurely. In addition to the increased risks associated with multiple birth, studies have also suggested that even infants born singly but conceived with ovulation stimulation are at increased risk for preterm birth than naturally conceived single births, the study authors pointed out.

The March of Dimes said it is critical for the American Society for Reproductive Medicine, the American College of Obstetricians and Gynecologists, and other clinical societies to develop clear guidelines on the use of fertility drugs to help prevent many premature births.

More than 540,000 babies are born too soon each year in the United States.  Preterm birth costs the nation more than $26 billion annually, according to the Institute of Medicine. It is the leading cause of newborn death, and babies who survive an early birth face the risk of lifelong health problems, such as breathing problems, mental retardation, cerebral palsy, developmental delays, and vision and hearing loss.  Even babies born just a few weeks too soon (34-36 weeks gestation, also known as late preterm birth) have higher rates of death and disability than full-term babies.  

The March of Dimes is the leading nonprofit organization for pregnancy and baby health.  With chapters nationwide, the March of Dimes works to improve the health of babies by preventing birth defects, premature birth and infant mortality.  For the latest resources and information, visit marchofdimes.com or nacersano.org. For free access to national, state, county and city-level maternal and infant health data, visit PeriStats, at marchofdimes.com/PeriStats.


'/>"/>
SOURCE March of Dimes
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Center for Fertility Preservation Uses Breakthrough Egg Freezing Technology to Offer Women a Viable Backup Plan
2. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
3. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
4. Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN(R) Compared With Other Progesterone Supplements
5. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
6. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
7. John DeVincenzo, MD, at the University of Tennessee Health Science Center Discovers First Evidence that RNA-interference Drugs Reduce Human Disease
8. FDA Announces Collaboration With Drugs.com
9. In a World First, Asda Announces Not for Profit Price on All Cancer Treatment Drugs
10. Reportlinker Adds Global HIV Drugs industry
11. Reportlinker Adds Ophthalmic Therapeutic Drugs: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
(Date:2/27/2017)... , February 27, 2017 Leading Countries, ... market is expected to grow at a CAGR of 8.9% ... expected to grow at a CAGR of 9.1% from 2016 to ... in 2027. ... this report will benefit you Read on to discover how ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in North America, today announced it would be offering some it’s exclusive product ... itself on crafting quality and unique baby clothing/feeding products, will team up with ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/25/2017)... ... , ... FCPX users now have the ability to sharpen a desired color ... users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, ... users can visually see the color range effected with ease all within Final ...
Breaking Medicine News(10 mins):